drugset / Trial / NCT07197450
Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism
Non-randomizedSequentialOpen-labelTreatment
Summary
This study aims to evaluate the safety and efficacy of a novel PTH replacement therapy drug in patients with hypoparathyroidism. The drug is an mRNA drug which will be translated into PTH after intravenous administration, to achieve the therapeutic effect.
Timeline
- Start
- 2025-05-20
- Primary completion
- 2026-07-15
- Completion
- 2026-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PTH1-84 mRNA | Messenger RNA (mRNA) | 20 ug | Intravenous |
| Subject | PTH1-84 mRNA | Messenger RNA (mRNA) | 40 ug | Intravenous |
| Subject | PTH1-84 mRNA | Messenger RNA (mRNA) | 80 ug | Intravenous |
| Subject | PTH1-84 mRNA | Messenger RNA (mRNA) | 120 ug | Intravenous |
| Subject | PTH1-84 mRNA | Messenger RNA (mRNA) | 160 ug | Intravenous |